| 1 |
Brunet M, Pastor-Anglada M. Insights into the pharmacogenetics of tacrolimus pharmacokinetics and pharmacodynamics. Pharmaceutics. 2022; 14(9): 1755.
|
| 2 |
Sikma MA, van Maarseveen EM, van de Graaf EA, Kirkels JH, Verhaar MC, Donker DW, et al. Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation. Am J Transplant. 2015; 15(9): 2301-13.
doi: 10.1111/ajt.13309
pmid: 26053114
|
| 3 |
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004; 43(10): 623-53.
doi: 10.2165/00003088-200443100-00001
pmid: 15244495
|
| 4 |
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2): 239-45.
doi: 10.1038/clpt.1981.154
pmid: 7249508
|
| 5 |
Prasad N, Patel MR. Infection-induced kidney diseases. Front Med. 2018; 5: 327.
|
| 6 |
Neuroimmunology Branch of Chinese Society for Immunology. Chinese guidelines for the diagnosis and treatment of myasthenia gravis (2020 version). Chin J Neuroimmunol Neurol. 2021; 28(1):1-12. [Article in Chinese]
|
| 7 |
Gerben AJ, Aarnoutse RE, Heijden JJ, Karin E J, Luuk BH. Effect of mild diarrhea on TAC exposure. Transplantation. 2012; 94(7): 763-7.
doi: 10.1097/TP.0b013e3182629e13
pmid: 22955188
|
| 8 |
Ramirez JA, Musher DM, Evans SE, Dela Cruz C, Crothers KA, Hage CA, et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. Chest. 2020; 158(5): 1896-911.
|
), Lingyan Yu1(